An interactive infographic to educate clinicians on advances in the therapeutic paradigm for patients with esophageal carcinoma.

Describe the pathogenesis of cold agglutinin disease (CAD), the mechanism of disease, its symptoms, and its possible consequences

Outline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma.

This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.

Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies

Assess the severity of hemophilia A according to clinical presentation and results of factor assays

Review diagnostic challenges that are specific to acquired, immune-mediated TTP (thrombotic thrombocytopenic purpura )

Describe the clinical burden of cold agglutinin disease